Modified BoNT/A With BoNT/B Binding for Longer Facial Dystonia Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for blepharospasm and hemifacial spasm using botulinum neurotoxin A (BoNT/A) are unpredictable, short-termed, and associated with toxicity, requiring frequent injections due to short duration of action, and lack an optimal dosage regimen that balances efficacy and safety across multiple muscles and sites.
Innovation Solution
A modified BoNT/A comprising a BoNT/A light-chain and translocation domain, and a BoNT/B receptor binding domain, which enhances retention and duration of action, allowing for higher doses and tailored administration to multiple sites without toxicity, providing a longer-lasting treatment.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of moving object
If conventional BoNT/A is used for treating blepharospasm and hemifacial spasm, then muscle relaxation effect is achieved, but the duration of action is short (12-14 weeks) requiring frequent injections
Solution Approach 1:
The patent modifies the BoNT/A molecule by changing its structural parameters - specifically using a BoNT/B receptor binding domain instead of the conventional BoNT/A receptor binding domain, while maintaining the BoNT/A light chain and translocation domain. This parameter change in the molecular structure results in prolonged duration of action exceeding 14 weeks, reducing the frequency of injections required for treatment maintenance.
2Duration of action of moving object
If higher doses of BoNT/A are administered to extend duration of action, then treatment longevity improves, but toxicity and unwanted facial muscle paralysis increase
Solution Approach 1:
The patent changes the molecular parameters of BoNT/A by substituting the receptor binding domain from BoNT/A to BoNT/B type. This structural modification allows the toxin to maintain prolonged duration of action (over 14 weeks) while exhibiting reduced toxicity and fewer unwanted effects such as facial muscle paralysis, even at higher doses compared to conventional BoNT/A.
3Reliability
If BoNT/A is administered to multiple muscles and sites to treat comprehensive symptoms, then treatment efficacy improves, but the complexity of dosage regimen increases
Solution Approach 1:
The modified BoNT/A formulation with BoNT/B receptor binding domain exhibits enhanced retention and prolonged duration of action that allows a single dose to effectively treat multiple muscles and sites. The extended duration enables one injection to provide comprehensive treatment coverage for various symptoms (blepharospasm, hemifacial spasm, and associated muscle twitching) without requiring complex multi-site dosing regimens, simplifying the treatment approach while maintaining high efficacy.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The modified BoNT/A offers improved safety and efficacy by enabling higher doses to be administered safely, reducing the frequency of injections and tailoring treatment to individual patient needs, thus improving the quality of life for patients with blepharospasm and hemifacial spasm.
Implementation Method 1
botulinum neurotoxin A (BoNT/A) selectively inhibits the release of acetylcholine from the presynaptic nerve terminals and thus blocks cholinergic transmission at the neuromuscular junction inducing a reduction in the muscle contraction and muscle tone
Data Source
AI summary
The present invention is directed to a modified botulinum neurotoxin A (BoNT/A) for use in treating a facial dystonia, including blepharospasm and hemifacial spasm, wherein the unit dose of the modified BoNT/A is at least 240 pg of modified BoNT/A, wherein the modified BoNT/A is administered by intramuscular injection to an affected muscle of a subject, wherein the total dose administered during the treatment is greater than 24,000 pg and up to 82,500 pg (e.g. up to 75,000 pg) of the modified BoNT/A, and wherein the modified BoNT/A comprises a BoNT/A light-chain and translocation domain (HN), and a BoNT/B receptor binding domain (HC domain).